ANI Pharmaceuticals Financial Ratios
NASDAQ: ANIPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
ANI Pharmaceuticals ratio analysis
ANI Pharmaceuticals earned a net margin of 8.9% in FY 2025, up from -3.0% a year earlier. Gross margin was 61.4% compared with a median of 59.3% over the prior 9 years. Return on equity reached 14.5%, meaning ANI Pharmaceuticals generated 0.14 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 0.57 versus 0.79 the year before, and the current ratio was 2.71. At the end of FY 2025, ANIP traded at 23.6 times earnings; across the 5 fiscal years shown, its year-end P/E ranged from 23.6 to 178.3, with a median of 64.9. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
ANI Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 23.62 | — | 64.87 | — | — | — | 120.30 | 37.55 | — | 178.29 |
| Price / sales | 1.78 | 1.75 | 2.04 | 2.07 | 2.69 | 1.67 | 3.45 | 2.83 | 4.21 | 5.39 |
| Price / book | 2.91 | 2.66 | 2.29 | 2.09 | 1.74 | 1.78 | 3.35 | 2.89 | 4.26 | 4.09 |
| Gross margin | 61.4% | 59.3% | 62.7% | 56.1% | 53.5% | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating margin | 12.6% | 0.1% | 9.6% | -11.2% | -18.4% | -7.7% | 7.9% | 17.5% | 16.0% | 15.6% |
| Net margin | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 3.0% | 7.7% | -0.6% | 3.1% |
| Free cash flow margin | 19.4% | 7.8% | 22.6% | -12.7% | 0.4% | 4.4% | 18.9% | 30.4% | 16.4% | 17.8% |
| Return on equity (ROE) | 14.5% | -4.6% | 4.3% | -15.3% | -12.8% | -11.5% | 2.9% | 7.9% | -0.6% | 2.3% |
| Return on assets (ROA) | 5.4% | -1.4% | 2.1% | -6.3% | -5.5% | -4.9% | 1.3% | 3.6% | -0.3% | 1.2% |
| Debt / equity | 0.57 | 0.79 | 0.66 | 0.91 | 0.86 | 0.95 | 0.87 | 0.36 | 0.42 | 0.00 |
| Current ratio | 2.71 | 2.72 | 3.57 | 3.46 | 3.68 | 2.17 | 3.04 | 0.92 | 3.35 | 3.22 |
| Revenue growth | 43.8% | 26.2% | 53.9% | 46.4% | 3.7% | 0.9% | 2.5% | 14.0% | 37.5% | 68.5% |
| EPS growth | — | -222.4% | — | — | — | -476.0% | -61.5% | — | -126.5% | -74.2% |